Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Cabaletta Bio, Inc. (CABA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/22/2023 4 Binder Gwendolyn (See Remarks) has filed a Form 4 on Cabaletta Bio, Inc.
Txns: Sold 10,700 shares @ $13.4052, valued at $143.4k
Sold 300 shares @ $13.8233, valued at $4.1k
Exercised 11,000 options to buy @ $1.01, valued at $11.1k
08/22/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201"
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/24/2023 8-K Quarterly results
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/19/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 4 Simon Mark (Director) has filed a Form 4 on Cabaletta Bio, Inc.
Txns: Granted 22,000 options to buy @ $11.18, valued at $246k
06/02/2023 4 Bollard Catherine (Director) has filed a Form 4 on Cabaletta Bio, Inc.
Txns: Granted 22,000 options to buy @ $11.18, valued at $246k
06/02/2023 4 HENRIQUES RICHARD C JR (Director) has filed a Form 4 on Cabaletta Bio, Inc.
Txns: Granted 22,000 options to buy @ $11.18, valued at $246k
06/02/2023 4 Brun Scott C. (Director) has filed a Form 4 on Cabaletta Bio, Inc.
Txns: Granted 22,000 options to buy @ $11.18, valued at $246k
06/01/2023 SC 13G Bain Capital Life Sciences Opportunities III, LP reports a 5% stake in Cabaletta Bio, Inc.
06/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan"
05/26/2023 SC 13G Flynn James E reports a 5.9% stake in Cabaletta Bio, Inc.
05/19/2023 4 Binder Gwendolyn (See Remarks) has filed a Form 4 on Cabaletta Bio, Inc.
Txns: Sold 22,000 shares @ $11.8106, valued at $259.8k
Exercised 22,000 options to buy @ $1.01, valued at $22.2k
05/19/2023 144 Form 144 - Report of proposed sale of securities:
05/18/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between the Company, Cowen and Company, LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC as representatives of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"Cabaletta Bio Announces Pricing of Public Offering of Common Stock"
05/18/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/16/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update"
05/02/2023 8-K Quarterly results
05/01/2023 8-K Quarterly results
04/27/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/21/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio, Inc. Corporate Presentation, furnished herewith",
"- IND application cleared within 6 months of in-licensing CABA-201 binder - CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be evaluated and the patient dosing intervals"
03/16/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy